0 projects

FORNY20-FORNY2020

Engineering cell lines to identify regulators of the unfolded protein response

Cellulær stressignalering er viktig i ulike kroniske sykdommer, inkludert kreft, nevrodegenerativ sykdom, fedme og diabetes. En av de sentrale stressignalveiene i cellen som blir kapret i sykdomstilstander er den ufoldede proteinresponsen (UPR). I UPR er det tre hovedsignalgrener som sammen hjelp...

Awarded: NOK 0.50 mill.

Project Period: 2023-2024

Location: Oslo

FORNY20-FORNY2020

KVAL: Development of a novel targeted therapy for prostate cancer

Prostatakreft (PCa) er den hyppigst diagnostiserte ikke-hudkreft hos menn i den vestlige verden (ca. 600 000 i de åtte store markedene), inkludert i Norge (rundt 4900 årlig). PCa kan kureres ved kirurgi eller strålebehandling hvis den er begrenset til prostata; Imidlertid presenterer omtrent en f...

Awarded: NOK 0.50 mill.

Project Period: 2021-2022

Location: Oslo

FRIMEDBIO-Fri prosj.st. med.,helse,biol

The unfolded protein response signaling drives prostate cancer

Cellesignalisering er kjernen i normal fysiologi og helse, mens dens forstyrrelser er nøkkelen til patologiske forhold. Ved kreft dereguleres en rekke signalveier som driver kreftprogresjon. Konsekvent er et stort antall medisiner som i dag brukes i klinikken, målrettet mot cellesignalisering. Må...

Awarded: NOK 12.0 mill.

Project Period: 2020-2024

Location: Oslo

PES2020-Prosj.etabl.støtte H2020

Feasibility study of CANscript - a prostate cancer biomarker and target discovery platform.

Oncoselect AS aims to identify new biomarkers and therapeutic targets for prostate cancer (PCa), the most commonly diagnosed nonskin cancer and the second most deadly cancer in men in the Western world. The current challenge in the clinic for PCa is that it is difficult to tell apart aggressive d...

Awarded: NOK 49,999

Project Period: 2018-2020

Location: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

Development of novel drugs for prostate cancer therapy

Prostatakreft er den mest vanlige formen for kreft og den nest hyppigste årsak til kreftrelaterte dødsfall hos menn. Mens tidlig diagnostisering har redusert dødelighet av prostatakreft, er det ingen kur for avansert sykdom. Følgelig blir en av seks menn diagnostisert med prostatakreft, og en av ...

Awarded: NOK 6.4 mill.

Project Period: 2014-2017

Location: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

Oslo Prostate Cancer Symposium ? From molecular biology to the clinic

We hereby request funds for a two-day international conference on the basic and translational research areas in the field of prostate cancer that will be held 14-16 May, 2014 at the University of Oslo. This conference is a significantly expanded follow-up to the inaugural Oslo Prostate Cancer Sy...

Awarded: NOK 0.17 mill.

Project Period: 2014-2015

Location: Oslo

KREFT-Offentlig kreftprogram

Development of biomarkers and identification of therapeutic targets for prostate carcinogenesis

Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer mortality in men in western countries, including Norway. Prostate cancer encompasses a biological continuum from a slow-growing indolent tumour to a highly a ggressive and potentially fatal form. A m...

Awarded: NOK 4.5 mill.

Project Period: 2009-2013

Location: Oslo

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Molecular mechanisms of androgen action

Androgens are essential for a wide range of important biological processes. These include the development and maintenance of male reproductive organs, hair cycle and skeletal muscle, as well as regulation of lipid metabolism and bone remodelling. Androgen s are implicated in pathological processe...

Awarded: NOK 6.2 mill.

Project Period: 2009-2013

Location: Oslo

YFF-Yngre, fremragende forskere

Toppforskningsprogrammets prosjekt ledet av Fari Saatcioglu

...

Awarded: NOK 4.2 mill.

Project Period: 2004-2007

Location: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Molecular mechanisms of androgen action and prostate carcinogenesis

Androgens have a pivotal role in the development and maintenance of the male reproductive system, the normal prostate, as well as the initiation and progression of prostate cancer . Prostate cancer is the most commonly diagnosed non-cutaneous cancer and s econd leading cause of cancer death in me...

Awarded: NOK 5.9 mill.

Project Period: 2004-2008

Location: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Molecular mechanisms of androgen action and prostate carcinogenesis

...

Awarded: NOK 0.75 mill.

Project Period: 2004-2005

Location: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Molecular mechanisms of androgen action in prostate cancer

...

Awarded: NOK 9.5 mill.

Project Period: 2000-2005

Location: Oslo